Loading…
Bliv Wellness LLC was cited for misbranding compounded semaglutide and tirzepatide products offered on its website, falsely representing itself as the compounder of these drugs when it was not. The company violated sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act by making false or misleading claims about the compounded drug products in its website labeling and advertising. These misbranded products were introduced into interstate commerce in violation of the FDCA.